1
Clinical Trials associated with Interferon gamma-primed mesenchymal stromal cells(Ossium Health)A Phase 1 Study to Evaluate Safety, Toxicity, and Potential Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
This study is a two strata, dose escalation Phase I clinical trial designed to assess the safety and determine the maximal tolerated dose (MTD) of allogenic cord tissue derived MSCs (cMSCs, stratum 1) and allogeneic, interferon-γ primed bone marrow MSCs (γMSCs, stratum 2). Each stratum is designed to independently accrue 3 children at a dose level 1 of 2x106 cells/kg and 6 children at dose level 2 of 10x106 cells/kg, resulting in 9 children in each stratum. The primary objectives are to determine the safety and toxicity of allogeneic cord tissue derived MSCs and allogeneic interferon-γ primed bone marrow derived MSCs.
100 Clinical Results associated with Interferon gamma-primed mesenchymal stromal cells(Ossium Health)
100 Translational Medicine associated with Interferon gamma-primed mesenchymal stromal cells(Ossium Health)
100 Patents (Medical) associated with Interferon gamma-primed mesenchymal stromal cells(Ossium Health)
100 Deals associated with Interferon gamma-primed mesenchymal stromal cells(Ossium Health)